Zealand Pharma Weight Loss Treatment Trial Shows up to 8.3% Reduction in Body Weight

MT Newswires Live09-09

Zealand Pharma (ZEAL) said Monday that results from a phase 1b trial of the dapiglutide treatment showed the estimated mean body weight had declined by up to 8.3% on a placebo-corrected basis after 13 weekly doses.

Dapiglutide was safe and well-tolerated in part 1 of the study, with no severe treatment-emergent adverse events and only one serious adverse event, which was not tied to the drug, the company said.

Part 2 of the trial is assessing higher doses of dapiglutide up to 26 milligrams over a 28-week treatment period, with results expected in the first half of 2025.

Zealand Pharma said it intends to advance the clinical development of dapiglutide into a phase 2b trial in people with overweight and obesity, with a launch expected in H1 2025.

The company also expects to assess the potential of dapiglutide in select obesity-related comorbidities, it said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment